# Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome

> **NCT01393223** · PHASE2 · COMPLETED · sponsor: **Lipella Pharmaceuticals, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Interstitial Cystitis

## Interventions

- **DRUG:** LP-08 80mg
- **DRUG:** Normal saline
- **DRUG:** LP-08 20mg

## Key facts

- **NCT ID:** NCT01393223
- **Lead sponsor:** Lipella Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2018-06-14
- **Final completion:** 2018-06-14
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2018-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01393223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01393223, "Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01393223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*